Mechanisms of progression of chronic renal damage

Journal of Nephrology

Volumn 12, Issue SUPPL. 2, 1999, Pages

  Klahr, Saulo ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

Angiotensin II; Nuclear factor KB; Smoking; Transforming growth factor ; Tumor necrosis; Vasoactive compounds

Indexed keywords

ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY TUBULE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEINURIA; REVIEW; SMOKING;

ANGIOTENSIN II; ANIMALS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; NF-KAPPA B; PROTEINURIA; SMOKING; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033154735     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. USRDS, 1998 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, 1998; 23-49.
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. Effect of angioterisin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med, 1993; 329: 1456-62.
3. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. Effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease N Engl J Med 1994; 330: 877-84.
4. Klag MJ, STielton PK, Randall BL, NeatonJD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and endstage renal disease in men. N Engl J Med 1996; 334: 13-8.
5. Maschio G, Alberti G, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N EnglJ Med 1996; 334: 939-15.
6. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, x- Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney hit 1997; 51: 1908-19.
7. Gruppo Italiano di Studi Epidemiologie! in Nefrologia (Gisen). A long term randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies.J Nephrol 1991; 3: 193-202.
8. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1978; 1: 146-9.
9. Muhlhauser I, Sauicki P, Berger M. Cigarette-smoking as a risk factor for macroproteinuria and proliferative rctinopathy in type 1 (insulin-dependent) diabetes. Diabetologia 1986; 29: 500-2.
10. Couper JJ, Staples AJ, Cocciolone R, Nairn J, Badcock N, Henning P. Relationship of smoking and albuminuria in children with insulin-dependent diabetes. DiabetMed 1994; 11: 666-9.
11. Ritz E, Benck U, Franck E, Keller C, Seyfarth S, Clorius J. Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease. J Am Soc Nephrol 1998; 9: 1798-804.
12. PetersonJC. Adler S, BurkartJM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter J. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
13. Risdon R, Sloper JC, De S'ardener HE. Relationship between renal function and histological changes found in renalbiopsy specimens from patients with persistent glomerular nephritis. Lancet 1968; 1: 363-6.
14. Schainuck LI, Striker GE, Cutler RE, Benditt ÉP. Structuralfunctional correlations in renal disease. II. The correlations. Hum Pathol 1970; 1: 631-41.
15. Striker GE, Schainuck LI, Cutler RE, Benditt EP. Structuralfunctional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum Pathol 1970; 1: 615-30.
16. EddyAA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994; 5: 1273-87.
17. Fine LG, Ong AC, Norman JT. Mechanisms of tubulo-interstitial injury in progressive renal diseases. EurJ Clin Invest 1993; 23: 259-65.
18. Gandhi M, Oison JL, Meyer TW. Contribution of tubular injury to loss of remnant kidney function. Kidney Int 1998; 54: 1157-65..
19. Thomas M, Nigel J, Brunskill K, Harris K, Bailey E, Pringle JH, Furncss P, Walls J. Proteinuria induces tubular cell turnover - a potential mechanism for tubular atrophy. Kidney Int 1999; 55: 890-8.
20. Alvestrand A, Gutierrez A, Bucht H, Bergstrom J. Reduction of blood pressure retards the progression of chronic renal failure in man.J Nephrol Dial Transplant 1988; 3: 624-31.
21. Brazy PC, Stead WW, Fitzwilliam JF. Progression of renal in-sufficienty role of blood pressure. Kidney Int 1989; 35: 670-6.
22. Tierney WM, McDonald CJ, Luft FG. Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis 1989; 13: 485-93.
23. Perry HMJr, MillerJP, FornoffJR, BatyJD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25: 587-94.
24. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle hypertrophy. Autocrine transforming growth factor l expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 451-61.
25. Roberts AM, Sporn MB. Transforming growth factor-. Adv Cancer Res 1988; 51: 107-45.
26. Ortiz A, Bustos C, Alcazar A, Lopez-Armada MJ, Plaza JU, Gonzalez E, EgidoJ. Involvement of tumor necrosis factor- in the pathogenesis of experimental and human glomerulonephritis. In: GrunfeldJP, BachJF, Kreis H, Maxwell MH, eds. Advances in Nephrology, St. Louis, Mosby, 1995; 53-77.
27. Barnes PJ, Karin M. Nuclear factor-kappa: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71.
28. Klahr S. Obstructive Nephropathy. (Nephrology Forum), Kidney Int 1998; 54: 286-300.
29. Diamond JR, Kees-Folts D, Ding G, Frye JE, Restrepo NC. Macrophages, monocyte peptide-1, and TGF-l in experimental hydronephrosis. AmJ Physiol 1994; 266: F926-F933.
30. MungerJS, HarpelJG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-: structural features and mechanisms of activation. Kidney Int 1997; 51: 1376-82.
31. Bottinger EP, Letterio JJ, Roberts AR. Biology of TGF- in knockout and transgenic mouse models. Kidney Int 1997; 51: 1355-60.
32. Malyankar UM, Almeida M, Johnson RJ, Pichler RH, Giachelli CM. Osteopontin regulation in cultured rat renal epithelial cells. Kidney Int 1997; 51: 1766-73.
33. Chua CC, Hamdy RC, Chua BH. Regulation of thrombospondin-1 production by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1997; 1357: 209-14.
34. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-7.
35. Hugo C, Pichler R, Shankland S, Couser VG, Hohnson RJ. Thrombospondin l (TSP1), and TGF- activating protein, precedes and predicts tubulointerstitial fibrosis in glomerular disease. Kidney Int 1998; 53: 302-11.
36. Schnermann JB, Zhu XL, Shu X, Yang T, Huang YG, Kretzler M, BriggsJP. Regulation of endothelin production and secretion in cultured collecting duct cells by endogenous transforming growth factor-beta. Endocrinology 1996; 137:5000-8.
37. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F. Endothelin-1 transgenic mice develop glonierulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-9.
38. Sanderson N, Factor V, Nag)- P, KoppJ, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS. Hepatic expression of mature transforming growth factor beta-1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sei USA 1995; 92: 7 2572-6.
39. McKay NG, Power DA, MacLeod AM, Haites NE. Increased fi-bronectin incorporation into extracellular matrix in response to platelet-derived growth factor is mediated by transforming growth factor beta. Exp Nephrol 1995; 3: 142.
40. Phillips AO, Steadman R, Topley N, Williams JD. Elevated Dglucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor. AmJ Pathol 1995; 147: 362-74.
41. Egido J, Gomez-Chiarri M, Ortiz A, Bustos C, Alonso J, Gomez-Guerrero C, Gomez-Garre P, Lopez-Armada MJ, Plaza J, Gonzalez E. Role of tumor necrosis factor-a in the pathogenesis of glomerular diseases. Kidney Int 1993; 43 (suppl 39):S59-S-64.
42. Baud L, Fouqueray B, Philippe C, Amram A. Tumor necrosis factor alpha and mesangial cells. Kidney Int 1992; 41: 600-3.
43. Kaneto H, MorrisseyJ, McCracken R, Ishidoya S, Reyes A, Klahr S. The expression of mRNA for tumor necrosis factor-a increases in the obstructed kidney of rats soon after unilateral ureteral ligation. Nephrology 1996; 2: 161-6.
44. Wolf G, Aberle S, Thaiss F, Nelson PJ, Kaensky AM, Neilson EG, Strahl RA. TNF-ce induces expression of the chemoattractant cytokine RANTES in cultured mouse mesangial cells. Kidney Int 1993; 44: 795-804.
45. Mulligan MS, Johnson KJ, Todd RF, Issekutz TB, Miyasaka M, Tamatani T, Smith CW, Anderson DC, Ward PA. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis.J Clin Invest 1993; 91: 577-87.
46. Schreiner GF, Harris KP, Purkerson ML, Klahr S. Immunological aspects of acute ureteral obstruction: immune cell infiltrate in the kidney. Kidney Int 1988; 34: 487-93.
47. LarrickJW, Wright SG. Cytotoxic mechanism of tumor necrosis factor-α. FASEB J 1990; 4: 3215-23.
48. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629-34.
49. Baeurle PA, Henkel T. Function and activation of NF-kB in the immune system. Aiinu Rev Immunol 1994; 12: 141-79.
50. Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-kB and preservation of Ij.Ba by interleukin-10 and interleukin- 13.J Clin Invest 1997; 100: 2443-8.
51. Border WA, Ruoslahti E. Transforming growth factor-B in disease; the dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
52. Mizra A, Liu S-L, Frizell E, Zhu J, Maddukuri S, Martinez J, Davies P, Schwarting R, Norton P, Zern MA. A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kB. AmJ Physiol 1997; 272 (Gastrointest Liver Physiol 35): G281-G288.
53. Butler W. The nature and significance of osteopontin. Connective Tissue Res 1989; 23: 123-36.
54. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, Schwartz SM, Johnson RJ. Tubulointerstitial disease in glomerulonephritis; potential role of osteopontin (uropontin). AmJ Pathol 1994; 144: 915-26.
55. Johnson TS, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C, El Nahas AM. The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis.J Clin Invest 1997; 99: 2950-60.
56. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGFa and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461-8.
57. Nagle RB, Johnson ME.Jervis HR. Proliferation of renal interstitial cells following injury induced by ureteral obstrue-üon. Lab Invest 1976; 35: 18-22.
58. Pedagogos E, Hewitson T, Fräser I, Nicholls K, Becker G. Myofibroblasts and arteriolar sclerosis in human diabetic nephropathy. Am J Kidney Dis 1997; 29: 912-8.
59. Strutz, F, Oka'da H, Lo GW, Danoff T, Carone RL, TomaszewskiJE, Neilson EG. Identification and characterization of a fibroblast marker: FSP1. J Gell Biol 1995; 130: 393-405.
60. Tulchinsky E, Prokhortchouk E, Georgier G, Lukanidin E. A kB-related binding site is an integral part of the mtsl gene composite enhancer element located in the first intron of the gene. J Biol Chem 1997; 272: 4828-35.
61. Li J, Brazier AR. Angiotensinogen gene activation by angiotensin II is mediated by the Rel A (Nuclear Factor-kB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Molecular Endocrinology 1996; 10: 252-64.
62. Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 1996; 27 (part 2): 465-75.
63. Brasier AR, Li J, Wimbish KA. Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator. Hypertension 1996; 27: 1009-17.
64. MorrisseyJJ, Klahr S. Enalapril decreased nuclear factor KB activation in the kidney with ureteral obstruction. Kidney Int 1997; 52: 926-33.
65. Klahr S, MorrisseyJJ. Angiotcnsin II and Gene Expression in the Kidney. Am J Kidney Dis 1998; 31: 171-6.
66. Klahr S, MorrisseyJ. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 1997; 52 (suppl. 63): S-l 11-4.
67. MorrisseyJ], Klahr S. Differential effects of AE and AT-1 receptor inhibition on chemoattractants and adhesion molecular synthesis. Am J Physiol 1998; 274: F580-6.
68. MorrisseyJJ, Klahr S. The effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol 1999; 276: F39-F45.
69. Ma J, Hideki H, Fogo A, et al. Accelerated fibrosis and collagen deposition develop in the interstitinm of angiotensin type II (AT2) receptor null mutant mice during ureteral obstruction.J Am Soc Nephrol 1997; 8: 622A. © Società Italiana di Nefrologia